Opportunity Information: Apply for PA 14 137
Apply for PA 14 137
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Apr 7, 2014 and posted on Mar 3, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments City or township governments County governments State governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Independent school districts Public and State controlled institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) funding opportunity (PA-14-137) is a National Institutes of Health (NIH) research grant announcement designed to support high-impact studies that address Hepatitis C Virus (HCV) prevention and treatment in people who use substances and are therefore at elevated risk for acquiring or transmitting HCV. A central theme of the announcement is that substance-using populations often face overlapping risks and barriers, including co-infection with HIV or heightened vulnerability to HIV, limited access to consistent healthcare, and social or structural conditions that make prevention and treatment harder to deliver or sustain. The goal is to fund research that meaningfully reduces new HCV infections while improving the identification, linkage to care, and successful treatment of people already living with HCV, with a strong emphasis on approaches that can move the needle in real-world settings.
This opportunity specifically uses the NIH R01 mechanism, which is intended for well-developed research projects and can support both clinical and basic research. In practice, that means NIH was looking for rigorous projects that either clarify the biological, behavioral, or systems-level drivers of HCV risk and treatment outcomes among substance-using groups, or directly test interventions to prevent infection, improve screening and diagnosis, strengthen engagement in care, and increase cure rates. The announcement highlights that these efforts should focus on populations at risk due to substance use, and it explicitly includes people infected with or at risk for HIV, reflecting the frequent overlap between HIV and HCV epidemics and the shared prevention and care challenges involved.
The scientific priorities described in the announcement are anchored in public health impact: preventing new HCV infections and improving the efficiency and effectiveness of finding and treating existing infections. In other words, the FOA is not only about developing new knowledge in the abstract; it is oriented toward research that can be translated into better strategies, programs, or clinical practices for high-risk populations. The announcement notes that it is informed by the 2011 HHS Action Plan for viral hepatitis, which emphasized strengthening prevention, improving care and treatment, and reducing health disparities associated with viral hepatitis. By tying the FOA to that Action Plan, NIH signals that funded projects should align with national priorities around reducing the burden of viral hepatitis and improving outcomes among groups that are disproportionately affected.
From an administrative standpoint, this is a discretionary grant opportunity (not a formula or entitlement program) and does not require cost sharing or matching funds, which lowers the financial barrier for applicants. It was posted on March 3, 2014, created on April 7, 2014, and had an original and current closing date of May 7, 2017, with an archive date of June 7, 2017. The associated CFDA numbers listed are 93.279 (Drug Abuse and Addiction Research Programs) and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), reflecting the cross-cutting nature of the topic, spanning substance use research and liver/digestive disease research domains.
Eligibility for the program is broad and includes many types of organizations that commonly conduct NIH-funded research. Eligible applicants include state, county, city or township governments, special district governments, and tribal governments (federally recognized), as well as tribal organizations that are not federally recognized. Academic institutions are eligible, including public and state-controlled institutions of higher education, private institutions of higher education, and independent school districts. Nonprofits are eligible whether they have 501(c)(3) status or not (as long as they are not institutions of higher education), and public housing authorities/Indian housing authorities are also listed. For-profit entities can apply as well, including small businesses and other for-profit organizations. The announcement further clarifies that a range of mission-specific institutions and community-rooted organizations are eligible, including faith-based and community-based organizations, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Importantly, non-U.S. entities are allowed to apply, including foreign organizations and foreign institutions, and non-domestic components of U.S. organizations may participate; foreign components are permitted consistent with NIH policy.
NIH is the sponsoring agency, and the full announcement was made available through the NIH grants guide at the link provided in the source. For access or technical issues, the notice directs applicants to the NIH Office of Extramural Research (OER) webmaster contacts. Overall, the opportunity is best understood as an NIH push to advance clinically meaningful and scientifically rigorous HCV prevention and treatment strategies tailored to substance-using populations, with an emphasis on reducing transmission, closing gaps in diagnosis and treatment, and addressing the compounded risks seen when HCV intersects with HIV and other vulnerabilities.
Frequently Asked Questions (FAQs)
What is the "Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01)" funding opportunity?
It is a National Institutes of Health (NIH) research grant announcement (PA-14-137) that supports high-impact studies focused on Hepatitis C Virus (HCV) prevention and treatment among people who use substances and are at elevated risk of acquiring or transmitting HCV.
What is the main goal of this NIH announcement?
The goal is to fund research that reduces new HCV infections and improves the identification, linkage to care, and successful treatment of people living with HCV, especially through approaches that can work in real-world settings.
Why does the opportunity focus on substance-using populations?
The announcement emphasizes that people who use substances often face overlapping risks and barriers, such as limited access to consistent healthcare and social or structural conditions that make prevention and treatment harder to deliver or sustain. These factors can increase risk for HCV acquisition and reduce the likelihood of successful care and treatment.
Does the opportunity address HIV as well as HCV?
Yes. The announcement explicitly includes people infected with or at risk for HIV, reflecting the frequent overlap between HIV and HCV epidemics and shared challenges in prevention and care.
What type of grant mechanism does this opportunity use?
This opportunity uses the NIH R01 mechanism, which is intended for well-developed research projects.
What kinds of research projects are expected under an R01 for this topic?
NIH sought rigorous projects that either (1) clarify biological, behavioral, or systems-level drivers of HCV risk and treatment outcomes among substance-using groups, or (2) directly test interventions to prevent infection, improve screening and diagnosis, strengthen engagement in care, and increase cure rates.
Is the announcement limited to clinical research, or can it include basic research too?
It can support both clinical and basic research, as long as the work addresses HCV prevention or treatment issues relevant to substance-using populations.
What public health outcomes does NIH prioritize in this announcement?
The priorities are anchored in public health impact: preventing new HCV infections and improving the efficiency and effectiveness of finding and treating existing infections.
Is the research expected to be practical and applicable outside of academic settings?
Yes. The FOA is oriented toward research that can be translated into better strategies, programs, or clinical practices for high-risk populations, with a strong emphasis on approaches that can move the needle in real-world settings.
Is this funding opportunity connected to any national strategy or plan?
Yes. The announcement notes it is informed by the 2011 HHS Action Plan for viral hepatitis, which emphasized strengthening prevention, improving care and treatment, and reducing health disparities associated with viral hepatitis.
Does this opportunity require matching funds or cost sharing?
No. The opportunity does not require cost sharing or matching funds.
Is this a discretionary grant program or an entitlement/formula program?
It is a discretionary grant opportunity (not a formula or entitlement program).
Who is the sponsoring agency for this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
When was this opportunity posted and what were the relevant dates?
It was posted on March 3, 2014, created on April 7, 2014, had an original and current closing date of May 7, 2017, and an archive date of June 7, 2017.
What are the CFDA numbers associated with this funding opportunity?
The CFDA numbers listed are 93.279 (Drug Abuse and Addiction Research Programs) and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research).
What does it mean that there are two CFDA numbers?
It reflects the cross-cutting nature of the topic, spanning both substance use research and liver/digestive disease research domains.
Which organizations are eligible to apply?
Eligibility is broad and includes many organization types that conduct NIH-funded research. Eligible applicants include:
- State, county, city, township, and special district governments
- Tribal governments (federally recognized)
- Tribal organizations (not federally recognized)
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Independent school districts
- Nonprofits with 501(c)(3) status (not institutions of higher education)
- Nonprofits without 501(c)(3) status (not institutions of higher education)
- Public housing authorities/Indian housing authorities
- For-profit organizations (including small businesses)
- Faith-based and community-based organizations
- Hispanic-serving institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Are for-profit entities allowed to apply?
Yes. For-profit entities can apply, including small businesses and other for-profit organizations.
Are community-based and faith-based organizations eligible?
Yes. The eligibility list specifically includes faith-based and community-based organizations.
Can non-U.S. organizations apply?
Yes. Non-U.S. entities are allowed to apply, including foreign organizations and foreign institutions.
Can a U.S. organization include a foreign component in the project?
Yes. Non-domestic components of U.S. organizations may participate, and foreign components are permitted consistent with NIH policy.
What types of barriers and vulnerabilities does the FOA highlight for the target populations?
The FOA highlights overlapping risks and barriers such as co-infection with HIV or heightened vulnerability to HIV, limited access to consistent healthcare, and social or structural conditions that make prevention and treatment harder to deliver or sustain.
Where was the full announcement made available?
The full announcement was made available through the NIH grants guide at the link provided in the source information.
Who should be contacted for access or technical issues related to the announcement?
For access or technical issues, applicants are directed to the NIH Office of Extramural Research (OER) webmaster contacts.
How should someone summarize the overall purpose of this FOA?
It is an NIH effort to advance clinically meaningful and scientifically rigorous HCV prevention and treatment strategies tailored to substance-using populations, with an emphasis on reducing transmission, closing gaps in diagnosis and treatment, and addressing compounded risks when HCV intersects with HIV and other vulnerabilities.
Browse more opportunities from the same category: Education Health
Next opportunity: Supply Chain Hardware Integrity for Electronics
Previous opportunity: Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 137
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 137) also looked into and applied for these:
| Funding Opportunity |
|---|
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 14 152 Funding Number: PAR 14 152 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 14 160 Funding Number: PAR 14 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03) Apply for PA 14 164 Funding Number: PA 14 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21) Apply for PA 14 162 Funding Number: PA 14 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01) Apply for PA 14 163 Funding Number: PA 14 163 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) Apply for RFA DA 15 006 Funding Number: RFA DA 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R01) Apply for PAR 14 166 Funding Number: PAR 14 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Physical Sciences Oncology Centers (U54) Apply for PAR 14 169 Funding Number: PAR 14 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) Apply for RFA DA 15 007 Funding Number: RFA DA 15 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21) Apply for PA 14 176 Funding Number: PA 14 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01) Apply for PA 14 177 Funding Number: PA 14 177 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R01) Apply for PA 14 180 Funding Number: PA 14 180 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R21) Apply for PA 14 181 Funding Number: PA 14 181 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01) Apply for PAR 14 184 Funding Number: PAR 14 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revisions to Add Biomedical Big Data Training to Active NLM Institutional Training Grants in Biomedical Informatics (T15) Apply for RFA HG 14 006 Funding Number: RFA HG 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Core Center of Excellence Grant Program (P30) Apply for PAR 14 186 Funding Number: PAR 14 186 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 137", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.